On a roll, Apel­lis adds pos­i­tive PhII C3 da­ta for AMD drug, preps for PhI­II

Just days af­ter grab­bing a $60 mil­lion round to fund a Phase III pro­gram for a ri­val ther­a­py to Alex­ion’s Soliris, Louisville, KY-based Apel­lis …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.